In this way, the assay was designed to reflect ALKBH3 promoter methylation status which we then applied across 303 DNA samples, i.e. 8 breast-derived cell lines, 30 normal breast tissue samples and 265 primary breast tumors. Here, ALKBH3 is linked to breast neoplasm.